Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

Clinical data from Lidakol phase III studies

May 24, 1996

Preliminary phase II results for HNK20

May 24, 1996

RSV inhibitors presented by Wyeth-Ayerst

May 24, 1996

Antiinfluenza activity of LY-180299 described at congress

May 24, 1996

BW-1263W94 selected for clinical testing in CMV infection

May 24, 1996

NF-1153 demonstrates potent activity against influenza virus

May 24, 1996

Japanese researchers present anti-RSV agent at congress

May 24, 1996

NF-1062 evaluated for activity against rotavirus

May 24, 1996

Schering-Plough claims antiherpesvirus agents

May 24, 1996

Antifungal activity and good tolerability in phase I trial of L-743872

May 24, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...